ticagrelor and Shock

Ticagrelor as a P2Y12 receptor antagonist is recommended in patients with acute coronary syndrome without a primary cardiosurgical therapy. Severe relevant side effects, especially anaphylactic reactions, have not yet been described in the current literature.. We describe the first documented case in the current literature with a severe anaphylaxis after ticagrelor in a 76-year-old male patient with ST-elevation myocardial infarction. The diagnosis seems to be objectivated by the observed time-related life-threatening event after repetitive administration of ticagrelor and the rapid stabilization after adequate anaphylactic treatment.. This case should raise the awareness that a supposedly safe drug can still cause an anaphylactic shock.. Die Kasuistik beschreibt den ersten dokumentierten Fall mit einer klinisch gesicherten schweren Anaphylaxie nach Ticagrelor bei einem 76-jährigen männlichen Patienten mit ST-Hebungs-Myokardinfarkt (STEMI).

Topics: Adenosine; Aged; Humans; Male; Platelet Aggregation Inhibitors; Shock; ST Elevation Myocardial Infarction; Ticagrelor